Accessibility Menu
TherapeuticsMD logo

TherapeuticsMD

(NASDAQ) TXMD

Current Price$2.04
Market Cap$23.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-96%
5 Year-96%
1 Year+77%
1 Month-11%
TherapeuticsMD last closing stock price
MetricPriceDate
Last closeUSD 2.042026-07-16
TherapeuticsMD stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.49%USD 2.012026-07-09
1 month-10.92%USD 2.292026-06-16
3 month-1.45%USD 2.072026-04-17
Year to date+25.15%USD 1.632025-12-31
1 year+77.39%USD 1.152025-07-16
3 year-48.61%USD 3.972023-07-17
5 year-95.92%USD 50.002021-07-16
Since inception-95.92%USD 50.002011-10-31

TherapeuticsMD Financials at a Glance

Market Cap

$23.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.35M

Net Income (TTM)

$179.00K

EPS (TTM)

$0.02

P/E Ratio

132.47

Dividend

$0.00

Beta (Volatility)

1.12 (Average)

Price

$2.04

Volume

124

Open

$2.08

Previous Close

$2.04

Daily Range

$2.01 - $2.08

52-Week Range

$0.99 - $2.95

Estimated Earnings Date

Aug 17, 2026

TXMD News

Foolcom-Featured.png

TherapeuticsMD Swings to Profit in Q2

Motley Fool Markets TeamAug 12, 2025
computer home laptop getty 6.2

3 Awful Stocks Robinhood Investors Love -- and 1 of the Best

James HalleyAug 19, 2020
GettyImages-1006455620

3 Drug Stocks That Could Soar in 2020

Amar KhatriJun 10, 2020
Arrow Up Blue

Here's Why TherapeuticsMD Stock Is Rocketing Higher Today

Cory RenauerApr 29, 2020
yellow question mark

Is TherapeuticsMD Stock a Buy?

David Jagielski, CPAFeb 13, 2020
GettyImages-521470854

Why TherapeuticsMD's Stock Jumped Today

Brian FeroldiJan 21, 2020
stock sliding chalkboard

Here's Why TherapeuticsMD Fell as Much as 21.5% Today

Maxx ChatskoOct 24, 2019
stock up yellow chart getty

Here's Why TherapeuticsMD Jumped 25.6% in September

Maxx ChatskoOct 7, 2019
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About TherapeuticsMD

TherapeuticsMD helps women manage menopause symptoms and contraception needs. Its products offer relief from hot flashes and provide year-long birth control. The company licenses these solutions to other firms, making them widely available.

What’s in the Medicine Cabinet?

  • IMVEXXY: Vaginal insert for menopause-related pain; targets women with moderate-to-severe symptoms. (License revenue is 100% of total revenue, but not broken down by product.)
  • BIJUVA: Oral hormone therapy for hot flashes and night sweats during menopause; for women needing both estrogen and progesterone.
  • ANNOVERA: Year-long, patient-controlled contraceptive ring; for women seeking non-daily birth control.
  • Prenatal Vitamins: Prescription vitamins for pregnant women; sold under several brand names.
  • Preclinical Projects: Early-stage hormone therapies and delivery systems; not yet generating revenue.

Growth Spurts and Strategic Moves

  • Shifted to a royalty-only business model in December 2022, ending direct product sales.
  • Licensed U.S. rights to Mayne Pharma in 2022, securing 20-year royalty streams.
  • Expanded global reach through licensing with Theramex (Europe, Israel, other markets) and Knight Therapeutics (Canada).
  • Transferred Israel rights from Knight to Theramex in December 2024.
  • Reduced operating expenses by 45.5% year-over-year in Q2 2025.

Why This Company Isn’t Just Another Pill Pusher

TherapeuticsMD relies on a global network of partners to distribute its products, reducing operational costs. Its business model focuses on collecting royalties, not direct sales or manufacturing. The company’s portfolio includes unique, FDA-approved therapies for women’s health needs.

Five Things You Need to Know

  • Q2 2025 license revenue was $952,000, up 306.8% from Q2 2024.
  • All revenue in 2025 comes from licensing to Mayne Pharma, Theramex, and Knight.
  • Q2 2025 net income was $551,000, compared to a $1.09 million loss in Q2 2024.
  • Cash position was $6.07 million as of June 30, 2025.
  • Company has only one full-time employee and no direct product sales.

Bottom Line

TherapeuticsMD has transformed into a royalty-focused business with a lean structure. Its future depends on licensing income and resolving ongoing legal and financial challenges.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1

CEO

Marlan D. Walker

Website

www.therapeuticsmd.com

Headquarters

Boca Raton, FL 33431, US

TXMD Financials

Key Financial Metrics (TTM)

Gross Margin

90.31%

Operating Margin

-111.66%

Net Income Margin

5.34%

Return on Equity

0.66%

Return on Capital

-12.78%

Return on Assets

0.48%

Earnings Yield

0.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$23.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.57M

Volume

124

Avg. Volume

38.70K

Financials (TTM)

Gross Profit

$3.03M

Operating Income

-$3.74M

EBITDA

-$3.43M

Operating Cash Flow

$2.67M

Capital Expenditure

$0.00

Free Cash Flow

$2.67M

Cash & ST Invst.

$8.42M

Total Debt

$5.83M

TherapeuticsMD Performance Analysis

TherapeuticsMD annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 69,963,0002619.1%
20232023-12-31USD 1,302,000-98.1%
20242024-12-31USD 1,761,00035.3%
20252025-12-31USD 3,022,00071.6%
TherapeuticsMD sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30142.2%
Q32025-09-30-17.6%
Q42025-12-3113.9%
Q12026-03-31-18.9%
TherapeuticsMD annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -10.35-52.2%
20232023-12-31USD -0.98-90.5%
20242024-12-31USD -0.19-80.8%
20252025-12-31USD -0.05-74.0%
TherapeuticsMD sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30184.2%
Q32025-09-30-72.5%
Q42025-12-31-508.4%
Q12026-03-31115.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$724.00K

+84.2%

Gross Profit

$399.00K

+1.5%

Gross Margin

55.11%

N/A

Market Cap

$23.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$23.61M

N/A

Employees

1

N/A

Net Income

$95.00K

+114.5%

EBITDA

-$112.00K

+89.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$8.42M

+46.5%

Total Debt

$5.83M

-16.4%

Accounts Receivable

$3.21M

+7.2%

Inventory

$0.00

N/A

Long Term Debt

$4.82M

-19.1%

Short Term Debt

$1.01M

-0.4%

Return on Assets

0.48%

N/A

Return on Invested Capital

-11.46%

N/A

Free Cash Flow

$936.00K

+36.4%

Operating Cash Flow

$936.00K

+36.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PMNProMIS Neurosciences, Inc.
$14.75+10.90%
AYTUAytu BioPharma, Inc.
$2.19+1.39%
MPLTMapLight Therapeutics, Inc.
$37.88+1.77%
BFRIBiofrontera Inc.
$1.09-1.98%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.12-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$69.42-0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$30.23+0.10%
PATHUiPath
$12.30+0.02%

Questions About TXMD

What is the current price of TherapeuticsMD?

TherapeuticsMD is trading at $2.04 per share.

What is the 52-week range for TherapeuticsMD?

Over the past 52 weeks, TherapeuticsMD has traded between $0.99 and $2.95.

How much debt does TherapeuticsMD have?

As of the most recent reporting period, TherapeuticsMD reported total debt of $5.83M.

How much cash does TherapeuticsMD have on hand?

TherapeuticsMD reported $8.42M in cash and cash equivalents in its most recent financial results.

What is TherapeuticsMD’s dividend yield?

TherapeuticsMD does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services